1. Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
- Author
-
Rocco D, Battiloro C, Della Gravara L, and Gridelli C
- Subjects
- Anaplastic Lymphoma Kinase metabolism, Animals, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung metabolism, Gastrointestinal Diseases chemically induced, Gastrointestinal Diseases diagnosis, Humans, Lung Neoplasms diagnosis, Lung Neoplasms metabolism, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors pharmacology, Pyrimidines adverse effects, Pyrimidines pharmacology, Pyrimidines therapeutic use, Sulfones adverse effects, Sulfones pharmacology, Sulfones therapeutic use, Anaplastic Lymphoma Kinase antagonists & inhibitors, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use
- Abstract
The chimeric protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, resulting from the rearrangement of the homonym genes, is one of the currently targetable oncogenic drivers in anaplastic lymphoma kinase-positive non-small-cell lung cancer. In fact, four first- and second-generation anaplastic lymphoma kinase tyrosine kinase inhibitors, crizotinib (PF-02341066), ceritinib (LDK378), alectinib (CH5424802), and brigatinib (AP26113), are presently approved for clinical practice; however, these agents are not devoid of complications and thus should be administered meaningfully. Furthermore, third-generation inhibitors are currently under development to overcome acquired resistance mechanisms inevitably resulting from treatment with first- and second-generation tyrosine kinase inhibitors. Therefore, this article aims to provide a comprehensive state-of-the-art review about the pharmacodynamics, pharmacokinetics, safety, and tolerability profiles of currently available and promising under-development anaplastic lymphoma kinase tyrosine kinase inhibitors.
- Published
- 2019
- Full Text
- View/download PDF